Are there antibody-drug conjugates approved for Ocular Melanoma

Q: Are there antibody-drug conjugates approved for Ocular Melanoma

Based on current NCCN Guidelines for uveal melanoma, there are no antibody-drug conjugates ADCs specifically approved as standard treatment options for ocular melanoma at this time. The most relevant approved therapy that works through a similar immunological mechanism is tebentafusp-tebn Immuncore's Kimmtrak, which is a bispecific fusion protein not technically an ADC, but a different type of engineered protein. According to NCCN Guidelines: - Tebentafusp is a Category 1 recommendation highest

Ocular_melanomaMay 23, 2026Navis AI

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

Antibody-Drug Conjugates for Ocular Melanoma

Based on current NCCN Guidelines for uveal melanoma, there are no antibody-drug conjugates (ADCs) specifically approved as standard treatment options for ocular melanoma at this time.

What IS Approved: Tebentafusp

The most relevant approved therapy that works through a similar immunological mechanism is tebentafusp-tebn (Immuncore's Kimmtrak), which is a bispecific fusion protein (not technically an ADC, but a different type of engineered protein). According to NCCN Guidelines:

Tebentafusp is a Category 1 recommendation (highest level of evidence) for patients with HLA-A*02:01-positive metastatic uveal melanoma
It targets gp100, a protein found on melanoma cells
In a Phase III randomized trial, tebentafusp showed longer overall survival compared to investigator's choice chemotherapy (pembrolizumab, ipilimumab, or dacarbazine)
This represents a significant advance in uveal melanoma treatment

Why No ADCs Yet?

Uveal melanoma is biologically different from cutaneous (skin) melanoma. The NCCN Guidelines note that uveal melanomas:

Rarely have BRAF or KIT mutations (which some ADCs target)
Have different genetic profiles (commonly GNAQ mutations instead)
Show lower response rates to standard immunotherapies compared to cutaneous melanoma

Current Treatment Landscape

For metastatic uveal melanoma, NCCN Guidelines recommend:

Tebentafusp (for HLA-A*02:01-positive patients)
Immune checkpoint inhibitors (nivolumab/ipilimumab combination)
Targeted therapies (trametinib, a MEK inhibitor)
Chemotherapy options (dacarbazine, temozolomide, paclitaxel combinations)

Questions to Ask Your Oncologist

Have I been tested for HLA-A*02:01 status, and if so, am I a candidate for tebentafusp?
Are there any clinical trials testing new antibody-drug conjugates or other novel therapies for uveal melanoma that I might be eligible for?
What is the current standard of care recommendation for my specific stage and genetic profile?
Are there any emerging therapies in development that might be relevant to my case?

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

This is general information.

Upload your records for guidance specific to YOUR diagnosis — personalized to your biomarkers, stage, and treatment history.

Upload Records →Ask About Your Case →